MedTrace Logo

Endocrinal Dysfunction Among Children With Dilated Cardiomyopathy

NCT07567417 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-05

No results posted yet for this study

Summary

All patients in this study will be subjected to the following (as detailed in the attached patient's data sheet).

1. Clinical History: focusing on:

* Socio-demographic factors, especially age, gender, family history, and degree of consanguinity.
* Cardiac symptoms, such as feeding difficulties in the infant, exercise intolerance in older children, fatigue, dyspnea on exertion, heart failure symptoms.
2. Thorough clinical examination: focusing on:

* General condition.
* Anthropometric measures (weight, height, and body mass index).
* Vital signs (Including HR, BP, SO2, RR, Body temperature).
* Cardiac examination (including any associated murmur, signs up heart failure).
3. Severity of heart failure in children with dilated cardiomyopathy For all patients, they were classified according to Children's Ross HF classification.

Children's Ross HF classification is as follows\[17\]:

Class I: asymptomatic cases.

Class II: mild tachypnea or diaphoresis with feeding in infants, dyspnea on exertion in older children.

Class III: marked tachypnea or diaphoresis with feeding in infants, marked dyspnea on exertion, and prolonged feeding times with growth failure.

Class IV: tachypnea, retractions, grunting, or diaphoresis at rest are examples of symptoms.
4. Data collection: according to attached checklist for every patient involved in the study

Conditions

  • Assessment of Some Hormone Levels in Children With Dilated Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

Echocardiography assessment.

Assessment of Ejection fraction, Fractional shortening, and LV diameters/volumes to confirm diagnosis and severity.

DIAGNOSTIC_TEST

Laboratory investigations and Hormone assessment.

Blood samples will be collected at 9:00 a.m. to measure IGF-1, free T3 and T4, TSH, morning serum cortisol, ACTH, 25 OH vit D, calcium, parathyroid hormones, prolactin, and electrolytes (Na, K).

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07567417 on ClinicalTrials.gov